Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Liabilities (2023 - 2026)

Beta Bionics' Total Liabilities history spans 4 years, with the latest figure at $33.2 million for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 36.67% to $33.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $33.2 million, a 36.67% increase, with the full-year FY2025 number at $41.1 million, down 44.14% from a year prior.
  • Total Liabilities hit $33.2 million in Q1 2026 for Beta Bionics, down from $41.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for BBNX hit a ceiling of $228.8 million in Q3 2024 and a floor of $24.3 million in Q1 2025.
  • Historically, Total Liabilities has averaged $95.2 million across 4 years, with a median of $46.3 million in 2023.
  • Biggest five-year swings in Total Liabilities: skyrocketed 43.16% in 2024 and later crashed 88.68% in 2025.
  • Tracing BBNX's Total Liabilities over 4 years: stood at $51.4 million in 2023, then skyrocketed by 43.16% to $73.6 million in 2024, then tumbled by 44.14% to $41.1 million in 2025, then decreased by 19.35% to $33.2 million in 2026.
  • Business Quant data shows Total Liabilities for BBNX at $33.2 million in Q1 2026, $41.1 million in Q4 2025, and $35.3 million in Q3 2025.